27 results
8-K
EX-99.1
PTCT
PTC Therapeutics Inc
25 Jan 24
CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure
4:06pm
of the patient community and expert physicians, will be devastating for children and young men in Europe for whom no other disease-modifying therapies
8-K
PTCT
PTC Therapeutics Inc
19 Jul 23
Regulation FD Disclosure
12:00pm
and commercial landscape with an expert key opinion leader (the “Presentation”) on July 19, 2023 at 12:00 p.m. eastern time. The Company’s corporate
8-K
EX-99.2
PTCT
PTC Therapeutics Inc
21 Jun 23
Regulation FD Disclosure
7:30am
development of Evrysdi Expert Team
4 PIVOT-HD Interim Data Update Key Objectives for 12-Week Interim Data Readout Confirm the relationship of HTT
8-K
EX-99.1
rc0j2f 4aeghz2n7gd
7 Sep 22
PTC 2022 Corporate Presentation September 2022
7:31am
8-K
EX-99.1
uisxv0pk6dn3ihay0
9 Jun 22
Departure of Directors or Certain Officers
9:15am
8-K
EX-99.2
h88i8224env7z
10 Jan 22
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 40th Annual J.P. Morgan Healthcare Conference
7:21am
8-K
EX-99.1
iitnj7 c1w
30 Nov 21
Regulation FD Disclosure
8:16am
8-K
EX-99.1
eeerahmaj7al e7c
11 Jan 21
PTC Therapeutics Provides Update on R&D Pipeline and Commercial Progress at 39th Annual J.P. Morgan Healthcare Conference
7:05am
8-K
EX-99.2
sgqnopi07g182u9nxi9
11 Jan 21
PTC Therapeutics Provides Update on R&D Pipeline and Commercial Progress at 39th Annual J.P. Morgan Healthcare Conference
7:05am
8-K
EX-2.1
o9bdak26q tzuxh1mt3v
6 May 20
PTC Therapeutics to Acquire Censa Pharmaceuticals
4:38pm
424B5
fnvohboi
19 Sep 19
Prospectus supplement for primary offering
4:16pm
424B5
sbxkg
17 Sep 19
Prospectus supplement for primary offering
4:11pm
424B5
lkw 5jye6d0ezv2j
24 Jan 19
Prospectus supplement for primary offering
4:46pm
424B5
ey2dah5
22 Jan 19
Prospectus supplement for primary offering
4:23pm